Cagrilinatide and CagriSema: Amylin Analog Mechanism, Synergy with Semaglutide, and REDEFINE Trial Results
Most coverage of the new generation of obesity drugs focuses almost entirely on GLP-1 receptor agonists. Semaglutide, tirzepatide, retatrutide — they dominate the headlines, and for good reason. But there's a parallel story unfolding that is fundamentally different: a different hormone, a different brain pathway, and a different molecular approach to appetite suppression. That story is cagrilinatide — an entirely distinct class of drug, built from the scaffold of amylin, a pancreatic hormone that most people have never heard of. When you combine cagrilinatide with semaglutide and watch the results, you start to understand that the two major satiety pathways — the GLP-1 axis and the amylin axis — work on different enough circuits that doing both simultaneously is far more powerful than doing either alone.
What Is Amylin? The Hormone Behind the Drug
Co-Secreted With Insulin, Often Overlooked
Amylin (also called islet amyloid polypeptide, or IAPP) is a 37-amino acid peptide hormone produced by pancreatic beta cells — the same cells that make insulin. The key point: amylin is co-secreted with insulin. Every time your beta cells release a pulse of insulin in response to a meal, they simultaneously release amylin in a roughly 1:100 molar ratio (one amylin for every hundred insulin molecules).
Amylin is not a minor footnote to insulin biology. It plays a distinct and important regulatory role that complements insulin's glucose-lowering effects:
- Reduces appetite (satiety signaling): Amylin acts on amylin receptors in the brain — particularly in the area postrema and nucleus of the solitary tract (NTS) — to signal satiety and reduce meal size. This is a meal-termination signal.
- Slows gastric emptying: Like GLP-1, amylin slows the rate at which food leaves the stomach, modulating the pace of nutrient absorption and blunting post-meal glucose spikes.
- Suppresses glucagon: Amylin suppresses inappropriate glucagon secretion from alpha cells after meals, preventing post-meal blood sugar spikes from the hepatic glucose output direction.
Critically: amylin and GLP-1 both produce satiety and slow gastric emptying, but they do so through different brain circuits acting on different receptor systems. This difference is the pharmacological justification for combining them.
Amylin Receptor Biology: AMY1, AMY2, AMY3
Amylin receptors are complexes formed by the combination of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMPs):
- AMY1R = CTR + RAMP1
- AMY2R = CTR + RAMP2
- AMY3R = CTR + RAMP3
Amylin shows high affinity for AMY1R and AMY3R and variable activity at AMY2R. These receptors, like GLP-1R, are G-protein coupled receptors that signal primarily through Gs → adenylate cyclase → cAMP — the same second messenger system, but in different cellular contexts with different downstream effects.
The area postrema (AP) is the primary brain site for amylin's satiety effects. As a circumventricular organ (lacking a blood-brain barrier), the area postrema is directly exposed to circulating amylin and can detect peripheral amylin levels. AMY1R and AMY3R receptors are densely expressed in the AP, as confirmed in EBioMedicine research on cagrilintide brain mechanisms.
From the area postrema, amylin signals propagate to the NTS and lateral parabrachial nucleus (LPBN), which relay satiety information upward to the hypothalamus. The amylin satiety circuit is anatomically distinct from the vagal afferent → NTS circuit that carries GLP-1 satiety signals — they converge on some shared downstream pathways but come from different directions, which is why combining both signals produces more than additive suppression of food intake.
The Problem With Natural Amylin as a Drug: Fibrillation and Half-Life
Natural amylin has a severe limitation that makes it nearly impossible to use as a pharmaceutical: it is extraordinarily prone to forming amyloid fibrils. Human amylin spontaneously self-aggregates into fibrils in solution — the same type of misfolded protein structures associated with Alzheimer's and Parkinson's diseases. In fact, amyloid deposits in pancreatic tissue (made largely of misfolded amylin) are a pathological feature of type 2 diabetes.
Pramlintide (Symlin) was the first drug solution to this problem. It's an amylin analog approved in 2005 that replaces three key amino acid positions with proline residues (rat amylin sequence doesn't fibrillate at those positions), preventing fibril formation. Pramlintide works and produces meaningful improvements in post-meal glucose control when injected just before meals. But it has major practical drawbacks:
- Short half-life of 20–45 minutes, requiring injection three times daily before meals
- Injection timing constraints — it must be given within 15 minutes of a meal
- No compatibility with once-weekly dosing — impossible to make long-acting with pramlintide's structure
These limitations dramatically restrict pramlintide's real-world use. This is the gap that cagrilinatide was designed to fill.
What Is Cagrilinatide? Engineering a Long-Acting Amylin
Cagrilinatide (development code AM833, internal code NN0174-0833) is a long-acting amylin analog developed by Novo Nordisk. Its development was published in ACS Journal of Medicinal Chemistry, detailing how the molecule was engineered over several years of structure-activity relationship work.
Key Design Innovations vs. Pramlintide
1. Anti-fibrillation backbone: Cagrilinatide uses a backbone similar to pramlintide (not the natural human amylin sequence) to prevent fibril formation — the critical safety requirement for an injectable amylin analog.
2. Fatty acid acylation: A C20 fatty diacid chain was added to the N-terminus of the molecule, enabling reversible albumin binding — the same strategy used in semaglutide to extend circulation time. Notably, this was a surprising finding: GLP-1 cannot be lipidated at the N-terminus without losing potency, but the structural difference between amylin receptors and GLP-1R (amylin's N-terminus forms a loop stabilized by a disulfide bond rather than an alpha-helix that inserts into the receptor TM domain) tolerates N-terminal lipidation.
3. Extended half-life: Clinical PK data shows cagrilintide achieves a half-life of 159–195 hours (approximately 7–8 days), per ACS Publications chemistry development research — enabling once-weekly subcutaneous dosing without meal-timing restrictions.
The result is an amylin analog that acts on the same amylin receptors in the same brain regions as natural amylin, but circulates continuously for ~7 days rather than 20–45 minutes. The pharmacological profile is that of sustained, around-the-clock amylin receptor activation — providing persistent satiety signaling through the area postrema/NTS/LPBN circuit.
CagriSema: The Fixed-Dose Combination
CagriSema is Novo Nordisk's fixed-dose combination product containing:
- Cagrilinatide 2.4 mg (the amylin analog)
- Semaglutide 2.4 mg (the established GLP-1 receptor agonist)
Both are delivered in a single weekly subcutaneous injection.
The pharmacological logic is straightforward: semaglutide activates GLP-1 receptors on vagal afferents, the NTS, the hypothalamus, and peripheral tissues. Cagrilinatide activates amylin receptors (AMY1R and AMY3R) primarily in the area postrema, NTS, and LPBN — a different set of receptors acting on overlapping but distinct neural circuits. The two signals are not redundant; they are complementary at both the receptor level and the neural circuit level.
This is analogous to the reasoning behind tirzepatide's dual GLP-1/GIP mechanism, but the two hormonal axes being combined here are more fundamentally different from each other. GLP-1 and GIP are both incretins from the same molecular family. GLP-1 and amylin are from completely different hormonal families — one a gut hormone, the other a pancreatic peptide — that happen to converge on similar physiological goals (satiety and glucose regulation) through very different pathways.
REDEFINE Phase 3 Program: Clinical Results
The REDEFINE program is Novo Nordisk's Phase 3 clinical development program for CagriSema, enrolling approximately 4,600 adults with overweight or obesity across REDEFINE-1 and REDEFINE-2. Both trials were 68-week, double-blind, placebo-controlled studies with once-weekly subcutaneous CagriSema.
REDEFINE-1: Obesity Without Type 2 Diabetes
REDEFINE-1 enrolled 3,417 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. It had four arms: CagriSema 2.4/2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, and placebo.
Results at 68 weeks (per the Novo Nordisk REDEFINE-1 announcement):
Efficacy Estimand (treatment effect if all patients adhered):
- CagriSema 2.4/2.4 mg: 22.7% mean weight loss
- Semaglutide 2.4 mg alone: 14.9%
- Cagrilintide 2.4 mg alone: 11.5%
- Placebo: 2.3%
Treatment Policy Estimand (all randomized, including discontinuers):
- CagriSema: 20.4% weight loss
- Placebo: 3.0%
Notable secondary endpoints for CagriSema (efficacy estimand):
- Participants achieving ≥5% weight loss: 97.6%
- Participants achieving ≥20% weight loss: 60.2%
- Participants achieving ≥25% weight loss: 40.4%
- Participants achieving ≥30% weight loss: 23.1%
Half of participants with obesity reached BMI below 30 (non-obese range) with CagriSema, from a mean baseline BMI of 38.
The finding that 23.1% of participants lost ≥30% body weight with a pharmacological treatment — essentially one in four patients achieving what would have previously been considered bariatric surgery territory — is extraordinary and without historical precedent in a drug trial.
Compared to semaglutide alone, CagriSema produced:
- 5.5% additional weight loss (p<0.001)
- 8.9% additional weight loss vs. cagrilintide alone (p<0.001)
These data were published simultaneously in the New England Journal of Medicine and presented at the 2025 American Diabetes Association Scientific Sessions, as documented by American Diabetes Association meeting coverage.
REDEFINE-2: Obesity With Type 2 Diabetes
REDEFINE-2 enrolled 1,206 adults with overweight or obesity and type 2 diabetes. Results at 68 weeks, per Endocrinology Advisor's REDEFINE-2 coverage:
Efficacy estimand:
- CagriSema: 15.7% mean weight loss vs. 3.1% placebo
Treatment policy estimand:
- CagriSema: 13.7% weight loss vs. 3.4% placebo
Key glycemic endpoint: 22.9% of CagriSema participants achieved ≥20% weight reduction, compared to 0.5% with placebo. Weight loss of ≥5% was achieved in 83.6% of CagriSema participants vs. 30.8% placebo.
As typical in obesity drug trials, weight loss in T2D populations is somewhat lower than in non-diabetic populations — this is a well-documented phenomenon across GLP-1, GIP, and amylin-class drugs. Still, 15.7% weight loss in a T2D population is a clinically meaningful result, on par with tirzepatide in equivalent patient populations.
The Synergy Quantified
The REDEFINE-1 four-arm design allows direct quantification of how much cagrilinatide adds to semaglutide:
| Treatment | Weight Loss at 68 Weeks (Efficacy Estimand) |
|---|
| Placebo | 2.3% |
| Cagrilintide 2.4 mg alone | 11.5% |
| Semaglutide 2.4 mg alone | 14.9% |
| CagriSema 2.4/2.4 mg | 22.7% |
If the effects were simply additive, combining semaglutide (14.9%) and cagrilintide (11.5%) over placebo (2.3%) would predict: 14.9% + 11.5% − 2.3% = ~24.1% — suggesting the combination is approximately additive in weight loss terms. Whether there is true synergy (above the additive prediction) or merely additive effects is still being analyzed in more detail, but either interpretation supports the value of the combination: the two mechanisms access enough distinct biology that their effects stack.
How It Helps GLP-1-Resistant Patients
One of the most clinically important implications of CagriSema is its potential for patients who plateau or fail to respond adequately to GLP-1 agonists.
GLP-1 receptor agonist resistance is a real clinical phenomenon. Some patients on semaglutide or tirzepatide lose less weight than expected, or weight loss plateaus at relatively modest levels (5–10% rather than the trial averages). The causes are multifactorial: pharmacokinetic variability, receptor downregulation, partial GLP-1 receptor saturation, or fundamental differences in metabolic phenotype.
Cagrilinatide acts on entirely different receptors (AMY1R, AMY3R vs. GLP-1R, GIPR) and signals through different brain regions and circuits. Patients whose GLP-1R system is maximally activated or whose weight loss has plateaued on a GLP-1 drug may have substantial remaining responsiveness in the amylin receptor pathway. Adding cagrilinatide on top provides a second, independent satiety input that doesn't depend on the GLP-1 pathway being fully functional.
This is analogous to how combination antihypertensive therapy works: if blood pressure is not controlled by an ACE inhibitor, adding a calcium channel blocker works through a completely different mechanism and often achieves control where monotherapy couldn't.
Cardiovascular and Metabolic Secondary Endpoints
Both REDEFINE trials collected cardiovascular and metabolic secondary endpoints. The consistent findings across trials include:
- Waist circumference reduction: CagriSema produced ~13 cm greater waist reduction than placebo in REDEFINE-1
- Systolic blood pressure reduction: Significant vs. placebo
- Physical function improvement: Significant improvements in SF-36 physical functioning scores and the IWQOL-Lite-CT Physical Function instrument
- BMI normalization: 50.7% of CagriSema participants with baseline obesity reached BMI <30 by trial end
Novo Nordisk has initiated REDEFINE-11, a longer-duration trial that will explore further weight loss potential and safety of CagriSema at 2.4/2.4 mg beyond the 68-week endpoint of REDEFINE-1 and REDEFINE-2. This will be important for understanding durability and long-term cardiovascular outcomes.
FDA Regulatory Status
In December 2025, Novo Nordisk filed a New Drug Application (NDA) with the FDA for CagriSema as the first once-weekly combination of GLP-1 and amylin analogs for weight management, as announced in the Novo Nordisk FDA filing press release. The NDA is based on REDEFINE-1 and REDEFINE-2 data. FDA review is ongoing; approval is anticipated in 2026 if the standard review timeline holds.
Side Effect Profile
Well-Tolerated Relative to Efficacy
One of CagriSema's notable features in trial data is its low discontinuation rate for adverse events. In REDEFINE-1:
- Discontinuation due to adverse events: 6.0% with CagriSema vs. 3.7% with placebo
In REDEFINE-2:
- Discontinuation: 8.4% with CagriSema vs. 3.0% with placebo
These rates are comparatively low for a drug producing 20–23% weight loss — lower than retatrutide's 12–18% discontinuation rates and comparable to tirzepatide's rates in SURMOUNT-1.
The most common adverse events were mild to moderate gastrointestinal events (nausea, constipation, diarrhea) consistent with the GLP-1 receptor agonist class. Cagrilinatide by itself does not add substantially to GI adverse effects beyond those from semaglutide — amylin's main GI effect (gastric slowing) is largely shared with GLP-1, so the combination does not dramatically amplify GI side effects.
Notably, amylin analogs do not carry the thyroid C-cell tumor risk or MEN2 contraindication that applies to GLP-1 receptor agonists — this is a class-specific risk that applies to GLP-1R agonism, not amylin receptor agonism. The cagrilintide component does not add this risk.
Comparing CagriSema to Tirzepatide and Semaglutide
| Parameter | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | CagriSema |
|---|
| Mechanism | GLP-1R | GLP-1R + GIPR | GLP-1R + AMY1R/AMY3R |
| Receptor families | Incretin | Incretin + Incretin | Incretin + Amylin |
| Phase 3 mean weight loss | 14.9% | 20.9% | 22.7% |
| ≥20% weight loss | ~14.8% of patients | ~57% of patients | 60.2% of patients |
| ≥30% weight loss | Rare | ~15% of patients | 23.1% of patients |
| T2D weight loss | ~10% | ~15–17% | 15.7% |
| ADA dosing | Once weekly | Once weekly | Once weekly (combination) |
| Approval status | Approved | Approved | NDA filed Dec 2025 |
| Hypoglycemia risk (mono) | Very low | Very low | Very low |
| GI discontinuation rate | ~7% | ~5–7% | ~6% (REDEFINE-1) |
Frequently Asked Questions
Q: What is cagrilinatide, and how is it different from GLP-1 drugs?
A: Cagrilinatide is a long-acting synthetic analog of amylin — a pancreatic hormone co-secreted with insulin after meals — not a GLP-1 receptor agonist. While GLP-1 drugs (like semaglutide) activate GLP-1 receptors on vagal nerve endings and brain regions including the hypothalamus, cagrilinatide activates amylin receptors (AMY1R and AMY3R) primarily in the area postrema and nucleus of the solitary tract — different receptors in overlapping but distinct brain circuits. This mechanistic distinction is why combining cagrilinatide with semaglutide produces additive weight loss greater than either drug alone.
Q: What is CagriSema?
A: CagriSema is a fixed-dose combination product developed by Novo Nordisk containing cagrilinatide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (a GLP-1 receptor agonist), administered as a single once-weekly subcutaneous injection. It is the first drug to combine GLP-1 receptor agonism with amylin receptor agonism in a single weekly dose. In Phase 3 trials (REDEFINE-1), it produced 22.7% mean weight loss at 68 weeks — surpassing either component alone and on par with tirzepatide's SURMOUNT-1 results.
Q: What were the REDEFINE-1 trial results for CagriSema?
A: In REDEFINE-1 (3,417 adults with obesity or overweight without type 2 diabetes), CagriSema produced 22.7% mean weight loss at 68 weeks (efficacy estimand) and 20.4% (treatment-regimen estimand) vs. 2.3–3.0% with placebo. Secondary endpoints: 97.6% of participants achieved ≥5% weight loss, 60.2% achieved ≥20%, 40.4% achieved ≥25%, and 23.1% achieved ≥30% weight loss. Half of participants with obesity reached a non-obese BMI (<30) by trial end. The results were published in the New England Journal of Medicine and presented at ADA 2025.
Q: Does CagriSema work for patients with type 2 diabetes?
A: Yes. In REDEFINE-2 (1,206 adults with obesity or overweight and type 2 diabetes), CagriSema produced 15.7% mean weight loss at 68 weeks (efficacy estimand) vs. 3.1% with placebo. As is typical across all obesity drug classes, weight loss in T2D populations is somewhat lower than in non-diabetic populations. CagriSema also produced significant improvements in HbA1c, with a 1.91% reduction in a separate REIMAGINE-2 trial in T2D patients, alongside 14.2% body weight reduction.
Q: Why do amylin and GLP-1 work synergistically when combined?
A: Amylin and GLP-1 activate different receptor families (AMY1R/AMY3R vs. GLP-1R) in different but overlapping brain circuits. Amylin primarily signals through the area postrema, NTS, and lateral parabrachial nucleus via the calcitonin receptor/RAMP complex pathway. GLP-1 signals through vagal afferents and hypothalamic receptors via the Gs/cAMP pathway. Because these are different molecular targets in different receptor populations, both signals can be simultaneously active without competing or interfering — they add to, and in some circuits amplify, each other's satiety effects.
Q: How does cagrilinatide differ from pramlintide (Symlin), the older amylin drug?
A: Both are synthetic amylin analogs, but cagrilinatide is specifically engineered for once-weekly dosing. Pramlintide has a half-life of 20–45 minutes and must be injected three times daily within 15 minutes of each meal — making it burdensome in clinical practice. Cagrilinatide achieves a half-life of approximately 159–195 hours (7–8 days) through N-terminal fatty acid acylation that enables reversible albumin binding, allowing once-weekly injection without meal-timing restrictions. Cagrilinatide also uses structural modifications that prevent amyloid fibril formation.
Q: Could CagriSema help patients who plateau on GLP-1 drugs like semaglutide?
A: This is a strong theoretical and emerging clinical argument. Patients who plateau on GLP-1 agonists (where GLP-1R is maximally or near-maximally activated) may retain substantial responsiveness in the amylin receptor pathway, since amylin receptors are entirely distinct from GLP-1 receptors. Adding cagrilinatide activates a second, independent satiety circuit. Clinical evidence supports this: in REDEFINE-1, cagrilinatide alone produced 11.5% weight loss (roughly equivalent to semaglutide), suggesting robust independent efficacy. For semaglutide-experienced patients, adding the amylin pathway through CagriSema may restart stalled weight loss.
Q: What is the side effect profile of CagriSema?
A: The most common adverse events are mild-to-moderate gastrointestinal effects (nausea, constipation, diarrhea) consistent with the GLP-1 receptor agonist component. Adverse event discontinuation rates in REDEFINE trials were 6.0–8.4% with CagriSema — relatively low for a drug producing 20–23% weight loss, and comparable to semaglutide rates in STEP trials. Amylin receptor agonism does not add thyroid C-cell tumor risk (the GLP-1 class warning) — that risk is specific to GLP-1 receptor agonism. Overall, CagriSema's safety profile appears consistent with the GLP-1 drug class.
Q: Has CagriSema been approved by the FDA?
A: Novo Nordisk filed a New Drug Application (NDA) with the FDA in December 2025, seeking approval of CagriSema as the first once-weekly combination of GLP-1 and amylin analogs for weight management. FDA review is ongoing; approval is anticipated in 2026 under standard review timelines. CagriSema is not yet commercially available in the United States or other major markets.
Q: Is CagriSema better than tirzepatide?
A: Direct head-to-head trials between CagriSema and tirzepatide have not been conducted. In their respective Phase 3 obesity trials, CagriSema produced 22.7% weight loss (REDEFINE-1) and tirzepatide produced 20.9–22.5% weight loss (SURMOUNT-1) — essentially equivalent results, with CagriSema slightly higher by some measures. ADA meeting commentary noted CagriSema's results were "on par with tirzepatide" in SURMOUNT-1. The patient populations, trial durations, and protocols differ enough to make direct comparison uncertain. The drugs target different receptor combinations, meaning some patients may respond better to one than the other.
Q: What does the REDEFINE program show about the future of obesity medicine?
A: The REDEFINE data demonstrates that combining two distinct biological satiety mechanisms — the GLP-1 axis and the amylin axis — produces weight loss (20–23%) that matches or exceeds the dual incretin approach of tirzepatide. It validates the strategy of targeting orthogonal (mechanistically distinct) hormone pathways simultaneously, rather than simply amplifying a single pathway. With 23.1% of patients losing ≥30% of body weight, REDEFINE also establishes that pharmacological treatment can now achieve outcomes previously associated only with bariatric surgery in a meaningful proportion of patients.
Key Takeaways
- Amylin is not GLP-1: It's a distinct pancreatic hormone, co-secreted with insulin, that signals satiety through the area postrema, NTS, and lateral parabrachial nucleus — not via vagal GLP-1 receptor agonism. Different hormone, different receptors, different brain pathways.
- Cagrilinatide solves pramlintide's problems: A ~7-day half-life via N-terminal fatty acid acylation enables once-weekly dosing with no meal-timing restrictions — a quantum leap from pramlintide's 3x/day injection requirement.
- CagriSema = semaglutide 2.4 mg + cagrilinatide 2.4 mg: A single weekly injection activating both GLP-1R and AMY1R/AMY3R simultaneously.
- REDEFINE-1 results (non-T2D): 22.7% mean weight loss, 23.1% of patients losing ≥30%, 50.7% of obese participants achieving BMI <30 — all Phase 3 records for a combination pharmacotherapy.
- REDEFINE-2 results (T2D): 15.7% weight loss, consistent with other GLP-1 class drugs in T2D populations.
- FDA NDA filed December 2025: Approval anticipated 2026 under standard FDA review timeline.
- Well-tolerated: Adverse event discontinuation rates ~6% — low for a drug producing this degree of weight loss.
- Best candidates: Patients seeking maximum weight loss pharmacotherapy, those on semaglutide who have plateaued, and potentially those who are GLP-1-resistant (different receptor pathway may overcome GLP-1 pathway saturation).
Citations & References
- Novo Nordisk. "CagriSema 2.4mg/2.4mg demonstrated 22.7% mean weight reduction in REDEFINE 1." PR Newswire. 2025 Jun 22. https://www.prnewswire.com/news-releases/cagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html
- Novo Nordisk. "CagriSema NDA filing — first once-weekly GLP-1 and amylin analog combination." PR Newswire. 2025 Dec 18. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- Endocrinology Advisor. "REDEFINE-2: CagriSema 15.7% weight loss in T2D." 2025 Mar 12. https://www.endocrinologyadvisor.com/news/significant-weight-loss-cagrisema-redefine-2-trial/
- American Diabetes Association Meeting News. "REDEFINE trials advance combination treatment for weight management." 2025. https://www.adameetingnews.org/redefine-trials-advance-cagrilintide-semaglutide-combination-treatment-for-weight-management/
- Pharmacy Times. "CagriSema Demonstrates Significant Weight Loss in REDEFINE Clinical Trials." ADA 2025. https://www.pharmacytimes.com/view/ada-2025-cagrisema-demonstrates-significant-weight-loss-in-redefine-clinical-trials
- Gastroenterology Advisor. "Combining Cagrilintide With Semaglutide Amplifies Weight Loss Outcomes." 2025. https://www.gastroenterologyadvisor.com/news/combining-cagrilintide-with-semaglutide-amplifies-weight-loss-outcomes/
- 2-Minute Medicine. "Significant body weight reduction with cagrilintide-semaglutide therapy." 2025. https://www.2minutemedicine.com/significant-body-weight-reduction-with-cagrilintide-semaglutide-therapy/
- Andreassen SNS et al. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry. 2021. https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565
- Gribble FM et al. "Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3." EBioMedicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/
- Amylin brain circuitry. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0196978120301157
- Hay DL et al. "Amylin structure-function relationships and receptor pharmacology." British Journal of Pharmacology. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4882495/
- Indian Journal of Endocrinology and Metabolism. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide." 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11642503/
- Drug Topics. "CagriSema demonstrates superior HbA1c and weight loss in T2D (REIMAGINE 2)." 2026. https://www.drugtopics.com/view/cagrisema-demonstrates-superior-hemoglobin-and-weight-loss-results-in-type-2-diabetes
